In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Highlights From Pharmaceutical Strategic Alliances: The Importance Of Emerging Markets

Executive Summary

One of the key take-aways from a wide-ranging hour-long panel discussion on emerging markets at Elsevier Business Intelligence's 20th Pharmaceutical Strategic Alliances meeting was the notion that drugmakers cannot implement a one-size-fits-all strategy when building a presence in important new markets. Participating in the forum were Mervyn Turner, PhD, chief strategy officer of Merck , Jean-Michel Halfon, president and general manager of Pfizer's emerging markets business unit, and Robin Arnold, a consultant with IMS Health.

You may also be interested in...



Key Considerations For Launching Pharmaceutical Products In Emerging Markets

In light of growing revenue opportunities from emerging markets, we highlight tactics and successful examples for companies to leverage in overcoming challenges of low disease awareness and changing practice patterns.

Key Considerations For Launching Pharmaceutical Products In Emerging Markets

In light of growing revenue opportunities from emerging markets, we highlight tactics and successful examples for companies to leverage in overcoming challenges of low disease awareness and changing practice patterns.

Pfizer Shake Up Continues With Key Exits From Emerging Markets

In the wake of CEO Jeff Kindler's abrupt departure earlier this week, Pfizer has announced two key departures from its emerging markets team, suggesting greater changes may be on the way at the world's largest drug maker

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1132992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel